Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts ...
Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...
NEW YORK (MarketWatch) - Merck & Co. on Friday said it revised the filing timeline for its investigational treatment in development for atherosclerosis, or MK-0524B. The Whitehouse Station, NJ-based ...
Merck KGaA (XTRA:MRK) is back in focus after the U.S. FDA accepted its new drug application for pimicotinib, supported by late stage trial data, alongside previously reported earnings that exceeded ...
Merck MRK announced that the FDA had accepted the biologics license application (“BLA”) seeking approval for sotatercept, its novel investigational activin signaling inhibitor, as a potential ...
It’s been relatively smooth sailing for AstraZeneca and Merck’s Lynparza as it has gained indications in ovarian, breast, pancreatic and prostate cancer. But on Thursday, the companies reported a snag ...
Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results